Revvity reported third-quarter revenue of $729 million, up from $699 million a year earlier, and adjusted EPS from continuing operations of $1.38 versus $1.18. Pro forma revenue was $710 million, with 7% pro forma organic growth, and the company raised its full-year guidance. It also issued pro forma statements for the probable sale of its China Immunodiagnostics business for up to $200 million, expected to close by the end of 2027.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
